Page last updated: 2024-08-23

paclitaxel and Adrenocortical Carcinoma

paclitaxel has been researched along with Adrenocortical Carcinoma in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
da Conceição, BB; da Silva, JCL; de Paula Mariani, BM; Dos Santos Passaia, B; Fragoso, MCBV; Kremer, JL; Lima, K; Lotfi, CFP; Machado-Neto, JA; Zerbini, MCN1
Beuschlein, F; Hantel, C; Jung, S; Mussack, T; Reincke, M1
Bertherat, J; Beuschlein, F; Frantsev, R; Hantel, C; Jäckel, C; Lira, R; Mussack, T; Ozimek, A; Ragazzon, B; Reincke, M1
Ardito, A; Baudin, E; Berruti, A; Daffara, F; De Francia, S; Ferrero, A; Generali, D; Germano, A; Leboulleux, S; Papotti, M; Perotti, P; Priola, AM; Sperone, P; Terzolo, M; Volante, M1

Trials

1 trial(s) available for paclitaxel and Adrenocortical Carcinoma

ArticleYear
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
    European journal of endocrinology, 2012, Volume: 166, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib

2012

Other Studies

3 other study(ies) available for paclitaxel and Adrenocortical Carcinoma

ArticleYear
Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours.
    Investigational new drugs, 2020, Volume: 38, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Child, Preschool; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Paclitaxel; Prognosis; RNA, Messenger; Stathmin

2020
Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
    Endocrine-related cancer, 2014, Volume: 21, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Proliferation; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Mitotane; Paclitaxel; Polyethylene Glycols; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors.
    Molecular and cellular endocrinology, 2016, Mar-05, Volume: 423

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; DNA-Binding Proteins; Female; Humans; Interleukin-1 Receptor-Associated Kinases; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Mice, Nude; Nuclear Proteins; Paclitaxel; Proportional Hazards Models; Signal Transduction; Transcriptional Activation; Tumor Necrosis Factor alpha-Induced Protein 3; Tumor Necrosis Factor-alpha; Xanthones; Xenograft Model Antitumor Assays

2016